Table 2. National capacity for surveillance and containment of carbapenem-resistant Acinetobacter baumannii, European countries, 2019 (nā=ā37).
| Country | NRL | Routine referral of suspected CRAb isolates to NRL | National system for surveillance | National recommendation or obligation for notification | National guideline on phenotypic carbapenem susceptibility testing | National guideline on molecular characterisation of carbapenem resistance | National recommendation or guideline on infection control measures for CRAb | National plan for containment of CRAb | National policy or guideline on screening | |
|---|---|---|---|---|---|---|---|---|---|---|
| Albania | Yes | No | No | No | No | No | No | No | No | |
| Austria | Yes | Subset of isolates | Voluntary | No | No | No | No | No | Selective screening | |
| Belgium | Yes | Subset of isolates | Mandatory | Yes | Yes | No | For single cases and outbreaks | Yes | Selective screening | |
| Bosnia and Herzegovinaa | No | NA | No | No | No | No | No | No | No | |
| Bulgaria | Yes | Subset of isolates | Voluntary | No | Yes | No | For single cases and outbreaks | In preparation | No | |
| Croatia | No | NA | Mandatory | No | No | No | In preparation for single cases | No | Selective screening | |
| Cyprus | No | NA | Voluntary | No | No | No | No | No | No | |
| Czechia | Expert laboratoryb | Subset of isolates | No | No | No | No | No | No | No | |
| Denmark | Yes | All isolates | Mandatory | No | Yes | No | For single cases and outbreaks | Yes | Selective screening | |
| Estonia | No | NA | No | In preparation | No | No | No | No | No | |
| Finland | Expert laboratoryb | Subset of isolates | Mandatory | Yes | No | Yes | For single cases and outbreaks | Yes | Selective screening | |
| France | Yes | All isolates | Voluntary | No | Yes | No | No | No | No | |
| Germany | Yes | Subset of isolates | Mandatory | Yes | No | No | For single cases | No | No | |
| Greece | No | NA | Voluntary | Yes, for bacteraemias | No | No | For single cases and outbreaks | Yes | No | |
| Hungary | Yes | Subset of isolates | Mandatory | Yes | Yes | No | For single cases and outbreaks | In preparation | Selective screening | |
| Iceland | Expert laboratoryb | All isolates | Mandatory | Yes | Yes | Yes | For single cases and outbreaks | Yes | Selective screening | |
| Ireland | Yes | Subset of isolates | Mandatory | Yes | Yes | Yes | For single cases | No | No | |
| Italy | Expert laboratoryb | No | Voluntary | No | No | No | Yesc | No | No | |
| Kosovod | Expert laboratoryb | All isolates | No | No | No | No | No | No | No | |
| Latvia | Expert laboratoryb | No | Yes | Yes | No | No | No answer | No answer | No | |
| Lithuania | Expert laboratoryb | Subset of isolates | Mandatory | No | No | No | No | No | No | |
| Luxembourg | Expert laboratoryb | All isolates | No | No | No | No | No | No | No | |
| Malta | Expert laboratoryb | All isolates | Voluntary | Othere | No | No | Yese | No | No | |
| Montenegro | No | NA | No | No | No | No | No | No | No | |
| The Netherlands | Expert laboratoryb | No | No | No | No | No | Yes | No | No | |
| North Macedonia | Expert laboratoryb | No | Yesf | No | No | No | Nog | No | No | |
| Norway | Yes | All isolates | Mandatory | Yes | Yes | No | For single cases and outbreaks | Yes | Selective screening | |
| Poland | Expert laboratoryb | Subset of isolates | No | Yes | Yes | No | No | No | No | |
| Portugal | Yes | Subset of isolates | Mandatory | Yes | Yes | No | In preparation | In preparation | No | |
| Romania | Expert laboratoryb | Subset of isolates | Voluntary | No | No | No | In preparation | No | No | |
| Serbia | Yes | Subset of isolates | In preparation | No | No | No | No | No | No | |
| Slovakia | No | NA | No | Yes | No | No | No | No | No | |
| Slovenia | Expert laboratoryb | No | No | No | Yes | No | Noh | No | No | |
| Spain | Expert laboratoryb | Subset of isolates | In preparation | In preparation | Yes | No | In preparation | Yes | No | |
| Sweden | Yes | All isolates | Voluntary | Yes | Yes | No | Yes | Yes | Selective screening | |
| Turkey | Yes | No | Voluntary | Yes | Yes | No | For outbreaks | No | Selective screening | |
| UK | England | Yes | Subset of isolates | Voluntary | In preparation | Yes | No | For outbreaks | No | Yes |
| Northern Ireland | Yes | Subset of isolates | No | No | Yes | Do not know | Otherh | No | No | |
| Scotland | Yes | All isolates | Voluntary | Yes | Yes | No | For single cases and outbreaks | Yes | No | |
| Wales | Yes | All isolates | In preparation | No | Yes | No | Otheri | No | Selective screening | |
CRAb: carbapenem-resistant Acinetobacter baumannii; NA: not applicable; NRL: national reference laboratory; UK: United Kingdom.
a Results reported for Bosnia and Herzegovina only apply to Republic of Srpska.
b An expert laboratory fulfils the role of a NRL.
c Regional or local recommendations/guidelines apply.
d This designation is without prejudice to positions on status, and is in line with United Nations Security Council resolution 1244/99 and the International Court of Justice Opinion on the Kosovo declaration of independence.
e All organisms are isolated in one laboratory, which is interfaced with the surveillance unit.
f There is a national system for surveillance of multidrug-resistant microorganisms, but not specifically for CRAb. It is an obligation to report these microorganisms through the Centers of Public Health to the National Institute of Public health.
g There is no national recommendation or guideline on infection control measures for CRAb, but World Health Organization guidelines are followed.
h Guidelines available at institutional level.
i Part of the general policy on multidrug-resistant organisms.